Gemphire Therapeutics GEMP shares are trading lower after the company announced trial results for evaluating the safety, and tolerability of oral gemcabene.
The oral formulation of gemcabene is being developed for the treatment of hypercholesterolaemia which is an excess of cholesterol in the bloodstream. Three of the five patients tested showed decreases in TG levels while one patient discontinued treatment.
Gemphire shares were trading down 22.5% at 92 cents at time of publication.
Related Links:
Gemphire Therapeutics' Oral Cholesterol Drug Could Have $2.8 Billion Potential In U.S. Market
Acer Therapeutics Shares Plunge On FDA Complete Response Letter
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
